PLYMOUTH
MEETING, Pa., March 26,
2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-related
diseases, cancer, and infectious diseases, today announced
that Dr. Jacqueline Shea, President
and CEO will participate in The Novel Therapeutics Forum hosted by
Citizens JMP at Penn Medicine at 10:00 am
ET on April 2, 2024.
Dr. Shea will provide a brief overview of INOVIO and then
participate in a panel discussion entitled "Innovative Technologies
for Treating and Preventing Disease," which will be moderated by
Roy Buchanan, biotechnology analyst
at Citizens JMP.
The Citizens JMP Novel Therapeutics Forum will take place at the
Jordan Medical Education Center at the Perelman Center for Advanced
Medicine but will not be webcast.
About INOVIO
INOVIO is a biotechnology company focused
on developing and commercializing DNA medicines to help treat and
protect people from HPV-related diseases, cancer, and infectious
diseases. INOVIO's technology optimizes the design and delivery of
innovative DNA medicines that teach the body to manufacture its own
disease-fighting tools. For more information, visit
www.inovio.com.
Contacts
Media: Jennie
Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-citizens-jmp-novel-therapeutics-forum-at-penn-medicine-302100288.html
SOURCE INOVIO Pharmaceuticals, Inc.